Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of HIV integrase resistance mutations.

Current opinion in infectious diseases - 1 Feb 2013

Quashie Peter K, Mesplède Thibault, Wainberg Mark A

Abstract excerpt

PURPOSE OF REVIEW: Integrase strand transfer inhibitors (INSTIs) have become a key component of antiretroviral therapy since the approval of twice-daily raltegravir in 2007 and the more recent approval of elvitegravir in 2012. At the same time, a third compound, dolutegravir, is in late-phase clinical trials, being tested as part of a multidrug once-daily formulation comprising this INSTI and two other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Drug Combinations
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Mutation

Source

Identifiers

PMID: 23242340
DOI: 10.1097/QCO.0b013e32835ba81c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of HIV integrase resistance mutations.PMID 23242340Read ↗

Resistance to HIV integrase inhibitorsSemantic proximity Read ↗

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitorsSemantic proximity Read ↗

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.Semantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimensSemantic proximity Read ↗

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.Semantic proximity Read ↗

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.Semantic proximity Read ↗

Will drug resistance against dolutegravir in initial therapy ever occur?Semantic proximity Read ↗

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.Semantic proximity Read ↗

HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsSemantic proximity Read ↗

HIV drug resistance against strand transfer integrase inhibitors.Semantic proximity Read ↗

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.